Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 17, 2006 Billy Fisher	Vanda Shareholders Sleeping Better The latest news on the company's insomnia drug boosts the stock.
The Motley Fool May 2, 2007 Brian Lawler	Vanda Advancing The development-stage biotech releases first-quarter financial results. Investors, take note.
The Motley Fool March 21, 2007 Brian Lawler	Acadia Ascending Shares of Acadia Pharmaceuticals soared by more than 100% following successful results from a phase 2 trial for schizophrenia drug candidate ACP-103.
The Motley Fool September 27, 2007 Brian Lawler	A Step in a Winding Road for Vanda Vanda Pharmaceuticals has submitted a new drug application to the FDA for its lead drug, iloperidone, emphasizing a new approach to reduce safety issues. Investors, take note.
The Motley Fool November 12, 2007 Brian Lawler	Vanda Gets Set for a Busy 2008 Although it has no marketed products, Vanda Pharmaceuticals third-quarter reports set the stage for an exciting 2008. Investors. take note.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool August 3, 2007 Brian Lawler	Vanda Announces Some Late-Stage Maneuvers Vanda Pharmaceuticals gets ready for a busy remainder of 2007. Management awaits approval on three different compounds in the near future. Investors should be prepared for a potentially volatile road ahead.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool May 18, 2009 Brian Orelli	Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price.
The Motley Fool March 31, 2009 Brian Orelli	Pharma's Refreshing Bad News Schering-Plough and Eli Lilly both present data at scientific meetings over the weekend about drugs that failed their clinical trials, but it's not bad news.
The Motley Fool May 19, 2009 Brian Orelli	Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies.
The Motley Fool August 27, 2008 Brian Orelli	Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 1, 2007 Brian Lawler	A Closer Look at Vanda Vanda Pharmaceuticals is a development stage drug maker worth keeping an eye on. Later this year Vanda plans to submit a New Drug Application to the FDA for its anti-psychotic medication, iloperidone.
The Motley Fool June 27, 2008 Brian Lawler	Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool September 5, 2007 Billy Fisher	Lilly's Pipeline Continues to Produce Another schizophrenia drug from the company shows promise in a clinical trial, prompting the company to plan additional trials. This is the latest good news in what has been a good year for Lilly.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool February 29, 2008 Brian Lawler	FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder.
The Motley Fool April 19, 2004 Alyce Lomax	Eli Lilly's Drug Dependency Competitive concerns make Cymbalta and new drugs more important than ever.
The Motley Fool November 4, 2011 Brian Orelli	You Should Have Seen These Biotech Failures Coming Micro cap biotechs are a value for a reason.
The Motley Fool December 12, 2006 Matt Koppenheffer	The 5-Sigma Report A look at the stocks that saw serious volatility last week. Gallaher Group... Kyphon... Vanda Pharmaceuticals... Bank of New York... Pfizer...
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.
ifeminists September 13, 2006 Tony Zizza	When Did Teenage Schizophrenia Become A Coupon? American children between the ages of 13-17 are now being marketed to parents clipping coupons to have their children participate in clinical research studies in which investigational "drugs for schizophrenia" are used.
The Motley Fool December 29, 2003 Alyce Lomax	Lilly's Symbyax Gets Green Light Prozac has a new lease on life. The Food and Drug Administration recently approved Eli Lilly's well-known antidepressant in combination with Zyprexa for the treatment of bipolar depression.
The Motley Fool December 22, 2009 Brian Orelli	2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes."
The Motley Fool February 20, 2004 Alyce Lomax	A Downer for Lilly? The pharmaceutical giant confirms warnings on Zyprexa and the elderly. That warning had to do with a higher incidence of stroke in elderly users suffering from dementia.
The Motley Fool April 15, 2005 Brian Gorman	Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note.
The Motley Fool January 5, 2011 Sean Williams	2 Cash-Rich Micro Caps Worth a Look Strong cash positions and a profitable history make these companies potential winners.
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
The Motley Fool July 21, 2011 Brian Orelli	Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda.
Chemistry World June 27, 2012 Helen Bache	Schizophrenia: a disease of the brain? Scientists in China have unearthed further evidence that a malfunction of the immune system contributes to the development of schizophrenia.